SCIENTIFIC PROGRAM

  • Day 1 Tuesday - October 21, 2025
  • Day 2 Wednesday - October 22, 2025
  • Day 3 Thursday - October 23, 2025
  • Day 4 Friday - October 24, 2025
13:00 – 14:30 Panel I: MS Biomarkers Revisited: Imaging and fluid biomarkers and beyond in the era of new diagnostic criteria
Chairs: Murat Terzi, M. Ufuk Aluçlu
  Panelists: 
Özlem Ethemoğlu, Atay Vural, Bilgin Öztürk, Sedat Şen, Mehmet Fatih Yetkin
14:30 – 15:15 Satellite Symposium- Abdi İbrahim
Chair:  
Hüsnü Efendi
  Dimetil Fumarat ve Teriflunomid Tedavisinde Güncel Veriler ve MS’te Engellilik Kavramına Bakış
Serkan Demir, Mehmet Fatih Yetkin
15:15 - 15:30 Break
15:30 – 17:00 Panel II: Managing MS: Current Treatment Options and Clinical Approaches
Chairs: Ömer Faruk Turan, Egemen İdiman
  Panelists: 
Kadriye Ağan, Esra Gürsoy, Alev Leventoğlu, Semra Mungan, Cihat Uzunköprü, Destan Bünül
17:00-17:45 Satellite Symposium- Sanovel
Chairs: Ayşe Altıntaş, Özlem Ethemoğlu
17:00-17:45 Speakers: 
Mesude Tütüncü, Rabia Gökçen Gözübatık Çelik
17:45-18:00 Break
18:00-19:00 Panel III: Young Investigators & European Charcot Foundation Fellowship Community Special Session
Chairs:
Meral Seferoğlu, Rabia Koç
18:00 – 18:05 Welcome & Introduction
Meral Seferoğlu, Rabia Koç
18:05 – 18:20 The Role of ECF with Young Researchers in MS
Marjan Steppe
18:20– 18:35 Leadership & Innovation in MS Research: A Youth-Driven Approach
Sara Samadzadeh
18:35 – 18:50 Being an MS Master’s Student: Academic and Clinical Reflections
Abdülkadir Tunç
18:50 – 19:00 Panel Discussion / Q&A
19:00-20:00 Panel IV: Rehabilitation in MS
Chairs: Aysun Ünal, Gürdal Orhan
  Panelist:
Cognitive Rehabilitation: Serkan Özakbaş
  Panelist: 
Physical Rehabilitation: Mesrure Köseoğlu
  Panelist: 
Artificial Intelligence & Brain-Computer Interface: Tuncay Gündüz
20:00 – 20: 20 Rational Drug Use Session
Chair: Tahir Kurtuluş Yoldaş
  Panelist: 
Yaşar Altun
20:20-21:00 Break & Buffet Dinner on site
21:00-23:00 Panel V: Diagnosing MS and Related Diseases – A Special Evening Event
Chair: Sabahattin Saip
  Panelists: Münife Neyal, Özgül Ekmekçi, Sıla Usar, Burcu Altunrende, Haluk Gümüş
Case Presentations: Gökçen Gözübatık Çelik, Ali Özhan Sıvacı, İpek Güngör Doğan, Pınar Acar Özen, Bedriye Karaman, Duygu Arslan Mehdiyev
08:00-09:00 Poster Sessions
09:00-09:15 OFFICIAL OPENING & Presentation of the Istanbul MS days awards
Chairs: Rana Karabudak, Husnu Efendi, Orhun H. Kantarci, Aksel Siva
09:00-09:15 Opening address and a quick overview of the 10 years of Istanbul MS days
Aksel Siva, Rana Karabudak, Orhun H. Kantarci, Husnu Efendi & Jack P. Antel
09:15-09:30 Welcome address 1: The 45 years of MS in 15 minutes
Aksel Siva
09:30-09:45 Welcome address 2: Rumi: Between the absolutes of doing it wrong and right
Orhun H. Kantarci
09:45-10:00 Presentation of the Istanbul MS days award
Aksel Siva, Rana Karabudak, Orhun H. Kantarci, Husnu Efendi
10:00-10:30 Istanbul MS Days: Learning from our mistakes in defining diseases
Brain G. Weinshenker
10:30-10:45 Break
10:45-12:30 SESSION-1: Learning from mistakes in science
Discussants & Chairs
: Frauke Zipp, Riadh Gouider, Cavit Boz
10:45-11:00 Introduction to the session: "Opportunities lost by dismissing or trivializing  negative findings in MS research?"
Frauke Zipp
11:00-11:20 Learning from Mistakes
Janet Hafler
11:20-11:40 Mistakes in the society
Boris Zalc
11:40-12:00 Pitfalls of genomic “big-data”
Philip L. De Jager
12:00-12:30 Q & A, Discussion
12:30-13:30 Lunch & In-Lunch Satellite Symposium - Farmanova
Chair: Aksel Siva
  A New Era of B Cell Therapies: Ofatumumab
Celia Oreja-Guevara
13:30-15:00 SESSION-2: Microglia in MS
Discussants & Chairs:
Jack P. Antel, Samia Khoury, Erdem Tüzün
13:30-13:45 Introduction to the session - The old friend or new foe: why did we ignore microglia all these years?
Jack P. Antel
13:45-14:05 Dynamic and changing roles of microglia in MS
Bruce Trapp
14:05-14:25 More questions than answers from BTK inhibitor research in MS
Amit Bar-Or
14:25-14:45 Molecular imaging is the answer - Why are you afraid of PET?
Laura Airas
14:45-15:15 Q & A, Discussion
15:15-15:30 Break
15:30-17:30 SESSION-3: Modeling MS in the future
Discussants & Chairs
:Tanja Kuhlmann, Husnu Efendi, Magd Zakaria
15:30-15:45 Introduction to the session: Rethinking Models of MS: Bridging the Gaps Between Pathology, Prediction, and Progress
Tanja Kuhlmann
15:45-16:05 Modeling MS pathology: Going beyond EAE
Hans Lassmann
16:05-16:25 Modeling the future of MS research: clinical clues that help or mislead
Andrew Chan
16:25-16:45 Modeling the future of MS research: MRI clues that help or mislead
Nicola De Stefano
16:45-17:15 Q & A, Discussion
17:15-17:30 Break
17:30-19:15 SESSION-4: Impact of hormones in neuroimmunology
Discussants & Chairs
: Sandra Vukusic, Ayşe Altıntaş, Gülşen Akman Demir
17:30-17:45 Introduction to the session: Sex Matters in MS: Potential therapeutic inertia affecting treatment in women with MS compared to men
Sandra Vukusic
17:45-18:05 What might have been missed by not running sex-specific clinical trials in MS?
Kerstin Hellwig
18:05-18:25 Impact of sex hormone switches in neuroimmunology – MS and beyond
Burcu Zeydan
18:25-18:45 Impact of sex hormones on animal models of MS
Manu Rangachari
18:45-19:15 Q & A, Discussion
19:30 Opening Reception
08:00-09:00 Oral Abstract Presentations
09:05-11:00 SESSION - 5: Myelin gets sick early in MS
Discussants & Chairs: Catherine
Lubetzki, Aslı Tuncer, Murat Kürtüncü
09:05-09:20 Introduction to the session- Myelin is not the only actor in MS
Catherine Lubetzki
09:20-09:40 More questions than answers in remyelination trials in MS
Peter Calabresi
09:40-10:00 Interactions between astrocytes and oligodendroglia in MS
Daniel Reich
10:00-10:20 PET as a single quantitative remyelination marker for clinical trials
Bruno Stankoff
10:20-10:50 Q & A, Discussion
10:50-11:05 Break
11:05-12:50 SESSION - 6: Simplifying the clinical phenotype definitions of MS
Discussants & Chairs:
Andrew J. Solomon, Rana Karabudak, Refik Pul
11:05-11:20 Introduction to the session: Has the new diagnostic criteria increased or decreased the risk of misdiagnosis in MS globally?
Andrew J. Solomon
11:20-11:40 Single agnostic definition of MS – the imaging-clinical continuum
Orhun Kantarci
11:40-12:00 Extremes of MS - Aggressive versus benign
Ellen Mowry
12:00-12:20 Separation of targets for differing trial endpoints – PIRA vs. RAW
Daniel Ontaneda
12:20-12:50 Q & A, Discussion
12:50-13:50 Lunch & In-Lunch Satellite Symposium - Roche
Chair:
Aslı Tuncer
  Timing of Ocrelizumab in MS: Clinical Impact and Efficacy of On Time Initiation
Speaker: Angela Vidal Jordana
13:50-15:30 SESSION-7: Defining MS phenotypes by biomarkers
Discussants & Chairs:
Eric Thouvenot, Jorge Correale, Ugur Uygunoglu 
13:50-14:05 Introduction to the session: From Missteps to Milestones: Rethinking Biomarkers in MS Phenotyping
Eric Thouvenot
14:05-14:25 Biomarkers of pre-symptomatic disease in MS – lessons from RIS
Christine Lebrun-Frenay
14:25-14:45 Pre- and post-symptomatic immunophenotypes of MS
Heinz Wiendl
14:45-15:05 Should AI care for our definitions of MS phenotypes?
Vilas Menon
15:05-15:35 Q & A, Discussion
15:35-15:50 Break
15:50-17:35 SESSION-8: Risk factor mitigation in MS
Discussants & Chairs:
Nikolaos Grigoriadis, Eda Tahir Turanlı, Yeşim Beckman
15:50-16:05 Introduction to the session: Mitigation Starts with Recognition: The Cost Of not addressing risk of MS
Nikolaos Grigoriadis
16:05-16:25 Lessons from our mistakes in epidemiology of MS
Alberto Ascherio
16:25-16:45 Is the gut the new solution for the brain?
David Hafler
16:45-17:05 EBV vaccination or microbiome transfer – which is the better path forward for MS prevention?
Thomas Berger
17:05-17:35 Q & A, Discussion
17:35-17:50 Break
17:50-19:35 SESSION - 9: Larger than life clinical trials in MS
Discussants & Chairs:
Ludwig Kappos, Hans-Peter Hartung, Melih Tutuncu
17:50-18:05 Introduction to the session: Decades of Experience in MS Therapeutic Trials: Key Lessons Learned
Ludwig Kappos
18:05-18:25 Give me the ideal clinical trial in MS - what is amiss in the past ones?
Xavier Montalban
18:25-18:45 Real value of harmonization of imaging for clinical trials
Maria Pia Sormani
18:45-19:05 Loosing specificity while looking for commonality and sensitivity in MS trials
Jiwon Oh
19:05-19:35 Q & A, Discussion
20:00 Leave for dinner
08:00-08:45 Morning Satellite Symposium - Alexion
Chair: Ayşe Altıntaş
  Targeting the Source: Complement Blockade in NMOSD
Jin Nakahara, Melih Tütüncü
08:45-10:15 SESSION - 10: Don’t ignore cognition in MS
Discussants & Chairs:
Anat Achiron, Najib Kissani, Serkan Demir
08:45-08:55 Introduction to the session:  We protected the brain but lost the mind in MS!
Anat Achiron
08:55-09:15 Complex imaging signatures of cognitive decline in MS
Korhan Buyukturkoglu
09:15-09:35 Impact of ethnicity on cognition in MS
Nabeela Nathoo
09:35-09:55 Roadblocks to treating cognition sufficiently in MS
Claire Riley
09:55-10:15 Q & A, Discussion
10:15-10:30 Break
10:30-12:00 SESSION - 11: Imaging developments in MS
Discussants & Chairs:
Nur Yüceyar, Mohammad Ali Sahraian, Serhat Okar
10:30-10:40 Introduction to the session:  Rethinking what we are measuring by imaging by MRI and PET in MS
Serhat Okar
10:40-11:00 From 2D to 3D understanding of MS lesion specificty
Darin Okuda
11:00-11:20 What is going on in the deep gray matter in MS
Christina Azevedo
11:20-11:40 What is going on in the normal appearing white matter in MS
Cristina Granziera
11:40-12:00 Q & A, Discussion
12:00-13:00 Lunch & In-Lunch Satellite Symposium - Merck
Chair: Rana Karabudak
  Mavenclad in MS Treatment
Refik Pul
13:00-14:45 SESSION-12: Propensity for autoimmunity
Discussants & Chairs: Hayrettin Tumani, Tania Kümpfel, Dicle Güç
13:00-13:15 Introduction to the session:  Common Risk Pathways in Autoimmunity
Hayrettin Tumani
13:15-13:35 A bioinformatics architecture  of susceptibility to autoimmunity
Mika Gustaffson
13:35-13:55 Role of TCR as key to autoimmunity
Batu Erman
13:55-14:15 Autoimmune mechanisms of neurodegeneration
TBA
14:15-14:45 Q & A, Discussion
14:45-15:00 Break
15:00-16:45 SESSION-13: Don’t ignore the children
Discussants & Chairs:
Jacqueline Palace, Anne-Katrin Pröbstel, Sema Saltık
15:00-15:15 Introduction to the session: From Childhood to Adulthood: Unraveling CNS  Autoimmunity Across Ages
Jacqueline Palace
15:15-15:35 Why are CNS inflammatory disorders more aggressive in children
Naila Makhani
15:35-15:55 Autoimmune leukoencephalopathies in children
Silvia Tenembaum
15:55-16:15 Differences in children’s brain imaging compared to adults in MS
Matilde Inglese
16:15-16:45 Q & A, Discussion
16:45-17:00 Break
17:00-19:00 SESSION - 14: Advances in MOG and NMO autoimmunity
Discussants & Chairs:
Kazuo Fujihara, Nasrin Asgari, Paulus Rommer
17:00-17:15 Introduction to the session: Lessons From the Era of NMOSD as Distinct From MS at the Turn of the Millennium
Kazuo Fujihara
17:15-17:35 The Many Faces of MOG autoimmunity
Romain Marignier
17:35-17:55 Mechanism of action of MOG antibodies
Orhan Aktaş
17:55-18:15 What does MOG autoimmunity teach us about post-inflammatory CNS diseases?
Axel Petzold
18:15-18:35 The strange case of MOG- Why does it not progress like MS?
Eoin Flanagan
18:35-19:00 Q & A, Discussion
19:00-20:00 SESSION-15: Summary of the meeting
Chairs: Serhan Sevim, Nilüfer Kale İçen
Speakers: Serkan Özben, Mesude Tütüncü, Bilge Piri Çınar, Gülgün Uncu, Ahmet Kasım Kılıç
20:15 Departure for Farewell Dinner